We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+32.66%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.98B
AUM Growth
+$533M
Cap. Flow
+$206M
Cap. Flow %
10.36%
Top 10 Hldgs %
47.31%
Holding
123
New
37
Increased
37
Reduced
31
Closed
16

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$27.7M
2
GSK icon
GSK
GSK
+$26.1M
3
ABVX
Abivax
ABVX
+$25.2M
4
EXAS
Exact Sciences
EXAS
+$19.4M
5
DHR icon
Danaher
DHR
+$19.1M

Top Sells

Rank Stock Value
1
ZIMV
ZimVie
ZIMV
+$39.4M
2
NTRA icon
Natera
NTRA
+$38.6M
3
QURE icon
uniQure
QURE
+$31.4M
4
RVTY icon
Revvity
RVTY
+$22.2M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
51
Ascendis Pharma A/S
ASND
$16.7B
$10.3M 0.52%
+48,241
New +$9.96M
ISRG icon
52
Intuitive Surgical
ISRG
$121B
$10.2M 0.52%
18,062
+3,636
+25% +$1.94M
ILMN icon
53
Illumina
ILMN
$29.4B
$10.1M 0.51%
76,721
-46,953
-38% -$5.51M
ARDX icon
54
Ardelyx
ARDX
$1.24B
$10M 0.5%
1,715,129
+285,752
+20% +$1.59M
DVAX
55
DELISTED
Dynavax Technologies
DVAX
$9.32M 0.47%
605,976
-87,551
-13% -$964K
GPCR icon
56
Structure Therapeutics
GPCR
$3.49B
$8.87M 0.45%
127,561
-38,830
-23% -$1.59M
EWTX icon
57
Edgewise Therapeutics
EWTX
$4.39B
$8.37M 0.42%
337,340
-164,894
-33% -$3.31M
CPRX
58
DELISTED
Catalyst Pharmaceutical
CPRX
$8.36M 0.42%
358,168
+7,356
+2% +$164K
HUM icon
59
Humana
HUM
$46.7B
$8.31M 0.42%
32,462
+15,810
+95% +$4.14M
PNTG icon
60
Pennant Group
PNTG
$1.43B
$8.27M 0.42%
293,960
+255,980
+674% +$6.81M
MRNA icon
61
Moderna
MRNA
$21.5B
$7.9M 0.4%
+267,823
New +$7.28M
MOH icon
62
Molina Healthcare
MOH
$10.3B
$7.89M 0.4%
45,470
+36,000
+380% +$5.92M
REGN icon
63
Regeneron Pharmaceuticals
REGN
$68.8B
$7.79M 0.39%
10,097
-6,623
-40% -$4.5M
TYRA icon
64
Tyra Biosciences
TYRA
$1.82B
$7.32M 0.37%
278,564
+5,858
+2% +$108K
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$2.65B
$7.3M 0.37%
+317,182
New +$10.4M
ANAB icon
66
AnaptysBio
ANAB
$1.6B
$5.86M 0.3%
+120,927
New +$4.71M
BMRN icon
67
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.57M 0.28%
93,748
-52,894
-36% -$2.88M
ASMB icon
68
Assembly Biosciences
ASMB
$506M
$5.43M 0.27%
+159,676
New +$5.14M
IVVD icon
69
Invivyd
IVVD
$180M
$5.29M 0.27%
2,140,130
+92,865
+5% +$193K
CVS icon
70
CVS Health
CVS
$137B
$5.05M 0.25%
+63,696
New +$5.02M
ACAD icon
71
Acadia Pharmaceuticals
ACAD
$4.25B
$4.72M 0.24%
176,594
+12,357
+8% +$295K
PTGX icon
72
Protagonist Therapeutics
PTGX
$8.75B
$4.63M 0.23%
+52,961
New +$4.33M
ZBIO
73
Zenas BioPharma
ZBIO
$1.92B
$4.39M 0.22%
121,016
-37,726
-24% -$1.24M
RLAY icon
74
Relay Therapeutics
RLAY
$4.02B
$4.14M 0.21%
489,137
+10,081
+2% +$71.9K
ENGN icon
75
enGene Therapeutics
ENGN
$122M
$4.12M 0.21%
+455,835
New +$3.65M
1 2
3
4 5

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Eversept Partners held 123 positions worth $1.98B, up 37% from $1.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners deployed $206M of net new capital in Q4 2025, opening 37 new positions and adding to 37 existing holdings. Its largest new stake was Exact Sciences: 241,678 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $38.6M trimmed.

  • Eversept Partners's largest Q4 2025 buy was Exact Sciences: 241,678 shares worth $24.5M.
  • Eversept Partners added most to Avantor in Q4 2025, an estimated $27.7M increase.
  • Eversept Partners's biggest Q4 2025 reduction was Natera, cutting an estimated $38.6M.
  • Eversept Partners fully exited ZimVie in Q4 2025, selling an estimated $39.4M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.98B portfolio in Q4 2025.
  • Eversept Partners opened 37 new positions and closed 16 in Q4 2025.
  • Eversept Partners's portfolio value rose 37% quarter-over-quarter to $1.98B.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.